Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) heads into the weekend of December 20, 2025 with investors still digesting a fast-moving sequence of catalysts: fresh clinical data for its lead program REC-4881, a notable JPMorgan upgrade, and a burst of unusually heavy trading volume that has kept the stock in the spotlight.

Because U.S. markets are closed on Saturday, the most recent trading reference is Friday’s close (Dec. 19, 2025). RXRX last traded around $4.26 after a volatile week that included a one-day surge and a quick pullback. ^[1]

RXRX stock price action this week: the “upgrade pop” meets reality checks

RXRX’s latest burst of attention is tightly linked to what happened mid-week:

Dec. 17: shares jumped ~11% on very high volume as the JPMorgan upgrade narrative spread across the market. ^[2]
Dec. 18–19: the stock gave back some gains, closing $4.26 on Dec. 19 (with roughly 55M shares changing hands that day, according to widely tracked pricing feeds). ^[3]

That two-step pattern—big catalyst, then a fast reassessment—is common in clinical-stage biotech. The market tends to reprice the “best case” quickly, then turns to the less glamorous questions: How strong is the data really? What’s the regulatory path? How much cash gets burned getting there?

The core catalyst: REC-4881 TUPELO trial data in Familial Adenomatous Polyposis

The most fundamental driver behind the recent analyst enthusiasm is Recursion’s Dec. 8, 2025 disclosure of positive Phase 1b/2 results from the ongoing TUPELO trial of REC-4881 (an investigational allosteric MEK1/2 inhibitor) in familial adenomatous polyposis (FAP). ^[4]

Key takeaways from the company’s filing exhibit include:

Rapid on-treatment effect: At the Week 13 assessment, REC-4881 (4 mg QD) produced a median 43% reduction in total polyp burden among efficacy-evaluable patients (n=12), and 75% of evaluable patients showed reductions after 12 weeks. ^[5]
Durability after stopping therapy: At Week 25—12 weeks off therapy—82% of evaluable patients (9 of 11) maintained reductions, with a median 53% decrease from baseline. ^[6]
Natural history context: A companion registry analysis (patients resembling TUPELO inclusion criteria) found 87% of untreated patients experienced annualized increases in polyp burden (10% stable; 3% modest decrease). ^[7]
Clinically meaningful GI staging signal:40% of patients (4/10) achieved a ≥1-point improvement in Spigelman stage, a commonly used measure for upper GI disease severity and management decisions. ^[8]
Safety snapshot (so far): The safety profile was described as consistent with MEK1/2 inhibition; most treatment-related adverse events were Grade 1–2, with Grade 3 events in 15.8% of safety-evaluable patients and no Grade ≥4 treatment-related adverse events reported to date in the update. ^[9]

Recursion also framed the program as an early “platform validation” moment: REC-4881 was identified using an early version of its Recursion OS via phenotypic screening, later supported by mechanistic follow-up and then translated clinically. ^[10]

Why FAP matters for investors (beyond the science headline)

FAP is rare but medically severe, often leading to repeated procedures and surgeries. Recursion’s exhibit describes an estimated ~50,000 patients across the U.S. and EU5 and emphasizes that there are no approved pharmacotherapies addressing the underlying biology. ^[11]

That combination—high unmet need plus measurable biological endpoint changes—tends to attract analysts looking for “registrational pathway” optionality, even before a pivotal trial design is locked.

What Recursion says comes next: FDA talks and trial expansion in 2026

Recursion’s own “next steps” are unusually explicit for a single-arm, mid-stage update:

The company plans to engage the FDA in 1H26 to define a potential registration pathway. ^[12]
It also plans to expand the treated population (from ≥55 to ≥18 years old) and optimize dosing schedule in parallel. ^[13]
The company notes that REC-4881 has received Fast Track and Orphan Drug designation from the U.S. FDA and Orphan Drug designation from the European Commission. ^[14]

For RXRX stock watchers, that FDA engagement line is the bridge between “interesting data” and “possible approval plan.” The market will likely treat any concrete regulatory alignment (endpoints, trial size, durability requirements, safety monitoring) as the next major catalyst cluster.

Analyst reaction: JPMorgan’s upgrade and the shifting price-target map

The upgrade that lit the fuse

Multiple market outlets reported that JPMorgan upgraded RXRX from Neutral to Overweight/Buy and raised its price target to $11. ^[15]

TipRanks’ weekend recap adds color to the thesis as framed by JPMorgan analyst Priyanka Grover, highlighting a bullish view anchored on REC-4881 and also citing a second asset, REC-617, in platinum-resistant ovarian cancer. The same recap describes a model that assigns explicit probability-of-success assumptions and projects blockbuster-scale peak sales for REC-4881 if development succeeds. ^[16]

Why “the” analyst forecast depends on where you look

If you’ve ever wondered why price targets seem to shapeshift depending on the website, you’re not imagining it—different vendors sample different analyst universes, refresh on different schedules, and apply different averaging logic.

Here’s how the current landscape looks as of this late-December window:

A Nasdaq/Fintel write-up (dated Dec. 17, 2025) cited an average one-year price target of $6.46 (with a low of $3.03 and high of $10.50) based on its dataset at that time. ^[17]
MarketBeat described a more optimistic aggregated view (multiple buys/holds and a higher average target), while also underscoring the company’s weak reported fundamentals (more on that below). ^[18]
Markets Insider (Business Insider) reports 14 analysts with a median target of $11.29, a high estimate of $17, and a low estimate of $5—a wide spread that signals genuine disagreement about probability and timing, not just decimal-level quibbling. ^[19]

The practical takeaway: the Street isn’t uniformly bearish or bullish—it’s split on how likely REC-4881 (and the rest of the pipeline) is to convert into an approval path before cash burn and dilution become dominant.

Valuation takes: “discounted AI biotech” vs. “show me the cash flows”

Two widely read analysis styles are circulating right now:

Simply Wall St (Dec. 19, 2025) frames RXRX as potentially undervalued versus a narrative fair value around $7/share, while still emphasizing that sentiment is only “cautiously rebuilding” given weaker longer-term returns and ongoing risks like partner pullbacks or dilution. ^[20]
Trefis (Dec. 18, 2025) takes a blunt stance: Recursion is a “pure-play bet on future potential,” with no commercialized drugs yet, and collaboration revenue (for the nine months ended Sept. 30, 2025) cited at ~$34M—meaning investors are underwriting the pipeline and platform, not present-day product margins. ^[21]

These takes converge on a single point: RXRX valuation is less about today’s revenue line and more about whether REC-4881’s signal can be converted into a credible registrational plan—and whether Recursion’s platform can generate additional “real drugs, not just interesting biology.”

Model-based forecasts for Dec. 20, 2025: technical signals lean bearish

Quant and technical-forecast sites updated around Dec. 20, 2025 generally describe RXRX as technically weak-to-mixed despite the midweek pop:

CoinCodex’s technical summary (timestamped Dec. 20) labels sentiment as bearish based on its indicator set and shows a short-term forecast around $4.27 for Dec. 20 (with nearby day-by-day estimates). ^[22]
Intellectia’s technical view (also dated Dec. 20) similarly describes a bearish moving-average setup and highlights potential resistance levels around ~$5.17 and ~$5.53 and support around ~$3.99 and ~$3.63. ^[23]

Important nuance for readers: these model outputs are not clinical forecasts. They’re pattern-based interpretations of price/volume behavior. In biotech, one regulatory sentence can invalidate a year of chart signals—so treat technicals as a temperature reading, not a diagnosis.

Insider and filing-related headlines: what’s actually on record

Recent insider-related items have also fed into the news cycle, and they’re worth parsing carefully:

A Form 4 dated Dec. 15, 2025 shows 7,057 shares disposed of at $4.33, with the explanation indicating shares were withheld by the issuer to satisfy tax obligations related to RSU settlement—typically not an open-market “someone is bailing” signal. ^[24]
A Reuters/Refinitiv note carried by TradingView reports that CEO Christopher Gibson filed a Form 144 on Dec. 19, 2025, proposing to sell 40,000 restricted securities under a prearranged 10b5-1 plan (Form 144 filings permit sales within a window; they are not the same thing as an executed sale). ^[25]
Earlier in December, Investing.com also reported a CEO sale of 40,000 shares executed under a pre-arranged 10b5-1 trading plan (dated Dec. 5, 2025 publication), alongside conversions and a gift—context that matters, because planned selling is structurally different from discretionary selling. ^[26]

For long-only investors, insider headlines can look ominous in isolation. The more accurate approach is to separate (1) tax-related withholdings, (2) planned trading program activity, and (3) unplanned discretionary sales. The first two are often administrative; the third is the one that tends to move sentiment.

Fundamentals check: why some analysts remain cautious even after strong data

Even with encouraging clinical signals, several outlets point to a hard truth: Recursion is still a clinical-stage company with financials that can look ugly in traditional screens.

MarketBeat’s write-up around the JPM-driven move highlighted:

Quarterly EPS around ($0.36) (slightly better than some estimates)
Revenue reported at $5.18M versus materially higher expectations in the same period
Extremely negative margins/ROE typical of R&D-heavy clinical-stage biotech ^[27]

This matters because, in biotech, “great data” does not automatically mean “great stock” if the market believes the financing path to get from Phase 2 → approval is long, expensive, and dilutive.

What to watch next for RXRX stock in 2026

As of Dec. 20, 2025, the likely near-to-mid-term catalysts for Recursion Pharmaceuticals stock revolve around a few very specific questions:

Regulatory clarity for REC-4881 in FAP
Any update that confirms endpoints, duration expectations, or a registrational pathway—especially after the company’s stated plan to engage FDA in 1H26—could materially reshape expectations. ^[28]
Expanded dataset and durability confirmation
The market will want to see whether the durability signal (Week 25 off-therapy reductions) holds as sample sizes grow—and how tolerability looks across broader age ranges. ^[29]
Pipeline breadth beyond REC-4881
Sell-side optimism is increasingly bundling multiple assets into the story (including REC-617 in some commentaries). Sustained investor confidence will likely require more “second-program proof,” not just one standout dataset. ^[30]
Cash runway and partnership economics
Whether via collaboration monetization, disciplined spend, or capital raises, the funding narrative will remain a parallel driver to clinical news—especially for a company still building toward product revenue. ^[31]

Bottom line: why RXRX is trending on Dec. 20, 2025

Recursion Pharmaceuticals stock is in focus right now because it’s sitting at the intersection of three powerful market forces:

A credible clinical signal (rapid and durable polyp-burden reductions in FAP) ^[32]
A high-profile analyst upgrade that reframed the upside conversation (JPMorgan’s move to Overweight/Buy with an $11 target) ^[33]
A volatile tape that’s forcing investors to price not only the science, but also dilution risk, timelines, and the difference between platform promise and product reality ^[34]

For Google News/Discover readers, the cleanest summary is this: RXRX is being repriced as a “platform + lead-asset” biotech again—yet it’s still trading like a market that demands proof. The next decisive moves likely come from FDA-pathway clarity and larger, confirmatory clinical readouts—not from the charts.